Standard Contracts
DEPOSIT AGREEMENT by and among MOLECULAR PARTNERS AG and CITIBANK, N.A., as Depositary, and THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of June 18, 2021Deposit Agreement • March 9th, 2023 • Molecular Partners Ag • Biological products, (no disgnostic substances) • New York
DEPOSIT AGREEMENT, dated as of June 18, 2021, by and among (i) MOLECULAR PARTNERS AG, a corporation incorporated under the laws of Switzerland, and its successors (the “Company”), (ii) CITIBANK, N.A., a national banking association organized under the laws of the United States of America (“Citibank”) acting in its capacity as depositary, and any successor depositary hereunder (Citibank in such capacity, the “Depositary”), and (iii) all Holders and Beneficial Owners of American Depositary Shares issued hereunder (all such capitalized terms as hereinafter defined).
MOLECULAR PARTNERS AG SALES AGREEMENTSales Agreement • July 1st, 2022 • Molecular Partners Ag • Biological products, (no disgnostic substances) • New York
Molecular Partners AG, stock corporation (Aktiengesellschaft) organized under the laws of Switzerland (the “Company”), confirms its agreement (this “Agreement”) with SVB Securities LLC (the “Agent”), as follows:
MOLECULAR PARTNERS AG [●] American Depositary Shares, representing [●] Common Shares Underwriting AgreementUnderwriting Agreement • June 9th, 2021 • Molecular Partners Ag • Biological products, (no disgnostic substances) • New York
The Offered ADSs are to be issued pursuant to a deposit agreement (the “Deposit Agreement”), to be dated as of the Closing Date (as hereinafter defined) among the Company,
Indemnification Agreement dated as of [month] [day], [year] by and betweenIndemnification Agreement • April 22nd, 2021 • Molecular Partners Ag • Biological products, (no disgnostic substances)
Molecular Partners AG (the Company) Wagistrasse 148952 SchlierenSwitzerland [e-mail] and [Name of Director / Executive] (the Indemnitee and, together with the Company, the Parties and each, a Party) [address][e-mail] regarding the indemnification of the Indemnitee by the Company
ContractLicense Agreement • March 9th, 2023 • Molecular Partners Ag • Biological products, (no disgnostic substances)
[ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
LICENSE AND COLLABORATION AGREEMENT BY AND BETWEEN NOVARTIS PHARMA AG AND MOLECULAR PARTNERS AGLicense and Collaboration Agreement • March 9th, 2023 • Molecular Partners Ag • Biological products, (no disgnostic substances) • New York
This LICENSE AND COLLABORATION AGREEMENT (“Agreement”) is made as of this 13th day of December 2021 (“Effective Date”), by and between Novartis Pharma AG, located at Lichtstrasse 35, CH-4056 Basel, Switzerland (“Novartis”) and Molecular Partners AG, located at Wagistrasse 14, 8952 Zurich-Schlieren, Switzerland (“Licensor”). Novartis and Licensor are each referred to individually as a “Party” and together as the “Parties.”
ContractLicense Agreement • April 22nd, 2021 • Molecular Partners Ag • Biological products, (no disgnostic substances)
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
COLLABORATION AND LICENSE AGREEMENT by and between MOLECULAR PARTNERS AG and AMGEN INC. December 18, 2018Collaboration and License Agreement • April 22nd, 2021 • Molecular Partners Ag • Biological products, (no disgnostic substances) • New York
This Collaboration and License Agreement (the “Agreement”) is entered into as of December 18, 2018 (the “Effective Date”) by and between Molecular Partners Ag, a Swiss corporation having an address at Wagistrasse 14 8952, Zürich-Schlieren, Switzerland (“Molecular Partners”) and Amgen Inc., a Delaware corporation having an address at One Amgen Center Drive, Thousand Oaks, California 91320, United States of America (“Amgen”). Molecular Partners and Amgen are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
ContractOption and Equity Rights Agreement • April 22nd, 2021 • Molecular Partners Ag • Biological products, (no disgnostic substances)
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
RESEARCH AND DEVELOPMENT COLLABORATION AND OPTION AGREEMENTResearch and Development Collaboration and Option Agreement • March 14th, 2024 • Molecular Partners Ag • Biological products, (no disgnostic substances)
This Research and Development Collaboration and Option Agreement (this “Agreement”) is made and entered into effective as of 5 January 2024 (the “Effective Date”) by and between Orano Med, a French simplified joint-stock company, with registered office at 125 avenue de Paris, 92320 Chatillon, France (“Orano Med”), and Molecular Partners, a Swiss corporation, with registered office at Wagistrasse 14, 8952 Schlieren, Switzerland (“Molecular Partners”). Molecular Partners and Orano Med may be referred to herein individually as a “Party” or collectively as the “Parties”.
DISCOVERY ALLIANCE AGREEMENTDiscovery Alliance Agreement • April 22nd, 2021 • Molecular Partners Ag • Biological products, (no disgnostic substances) • New York
This Discovery Alliance Agreement (the “Agreement”) is entered into as of August 20, 2012 (the “Effective Date”) by and between (a) Molecular Partners AG, a corporation organized and existing under the laws of Switzerland, having its principal place of business at Wagistrasse 14, 8952 Zürich-Schlieren, Switzerland (“Molecular Partners”) and (b) Allergan, Inc., a Delaware corporation having a place of business at 2525 Dupont Drive, Irvine, California 92612 USA, and Allergan Sales, LLC, a Delaware limited liability company having a place of business at 2525 Dupont Drive, Irvine, California 92612 USA (Allergan, Inc. and Allergan Sales, LLC, together “Allergan”). Molecular Partners and Allergan are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
MOLECULAR PARTNERS AG 3,642,988 American Depositary Shares, representing 3,642,988 Ordinary Shares Underwriting AgreementUnderwriting Agreement • October 28th, 2024 • Molecular Partners Ag • Biological products, (no disgnostic substances) • New York
LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • April 22nd, 2021 • Molecular Partners Ag • Biological products, (no disgnostic substances) • New York
This License and Collaboration Agreement (the “Agreement”) is entered into as of May 3, 2011 (the “Effective Date”) by and between (a) Molecular Partners AG, a corporation organized and existing under the laws of Switzerland and having its principal place of business at Wagistrasse 14 8952, Zürich-Schlieren, Switzerland (“Molecular Partners”) and (b) Allergan, Inc., a Delaware corporation having a place of business at 2525 Dupont Drive, Irvine, California 92612 USA, and Allergan Sales, LLC, a Delaware Limited Liability Company having a place of business at 2525 Dupont Drive, Irvine, California 92612 USA (Allergan, Inc. and Allergan Sales, LLC, together “Allergan”). Molecular Partners and Allergan are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
